- Home
- JAZZ vs AFRM Comparison
JAZZ vs AFRM Comparison
Compare JAZZ & AFRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JAZZ | AFRM |
|---|---|---|
| Founded | 2003 | 2012 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.0B | 14.3B |
| IPO Year | 2007 | 2020 |
Fundamental Metrics
Financial Performance| Metric | JAZZ | AFRM |
|---|---|---|
| Price | $223.73 | $73.98 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 25 |
| Target Price | ★ $217.57 | $84.52 |
| AVG Volume (30 Days) | 765.4K | ★ 4.6M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 108.98 |
| EPS | ★ 4.43 | 0.90 |
| Revenue | $1,618,693,000.00 | ★ $3,224,412,000.00 |
| Revenue This Year | $6.22 | $30.78 |
| Revenue Next Year | $7.68 | $23.95 |
| P/E Ratio | ★ $50.77 | $82.17 |
| Revenue Growth | N/A | ★ 38.80 |
| 52 Week Low | $105.00 | $42.10 |
| 52 Week High | $243.32 | $100.00 |
Technical Indicators
Market Signals| Indicator | JAZZ | AFRM |
|---|---|---|
| Relative Strength Index (RSI) | 45.70 | 59.58 |
| Support Level | $224.23 | $72.86 |
| Resistance Level | $242.66 | $79.17 |
| Average True Range (ATR) | 6.87 | 4.27 |
| MACD | -2.13 | 0.39 |
| Stochastic Oscillator | 18.45 | 80.03 |
Price Performance
Historical ComparisonAbout JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
About AFRM Affirm Holdings Inc.
Founded in 2012, Affirm is a market leader in the buy-now, pay-later space with around $36 billion in transaction volume in fiscal 2025. Affirm offers both zero-interest financing, which is merchant subsidized, and interest-bearing loans, which function as personal loans that are approved on a per-transaction basis. Over 70% of Affirm's transaction volume comes from its interest-bearing loans, which also comprise the majority of its revenue. Affirm operates in the United States, which accounted for more than 95% of its revenue in 2025, but the firm has also expanded to Canada and the United Kingdom.